It's Time For a Quick Look at Inspire Medical Systems's Fundamentals

By Susan Ramirez • Monday, July 24 11:19 • Permanent Link

One of the losers of today's trading session was Inspire Medical Systems. Shares of the Medical instruments & supplies company plunged -4.7%, and some investors may be wondering if its price of $292.94 would make a good entry point. Here's what you should know if you are considering this investment:

INSP has an average analyst rating of buy and is -16.54% away from its mean target price of $351.0 per share
Its trailing earnings per share (EPS) is $-1.5
Inspire Medical Systems has a trailing 12 month Price to Earnings (P/E) ratio of -195.3 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-0.28 and its forward P/E ratio is -1046.2
The company has a Price to Book (P/B) ratio of 16.93 in contrast to the S&P 500's average ratio of 2.95
Inspire Medical Systems is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
The company has a free cash flow of $24.58 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.